Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Renuvion, manufactured by Apyx Medical (NASDAQ: APYX), has won the 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener.' The technology is the first and only FDA-cleared device for use after liposuction in body contouring treatments.
The recognition comes as consumer searches for 'sagging skin' increased by 168.7% in 2024. Renuvion's effectiveness is backed by over 90 evidence-based clinical publications, delivering long-lasting results from a single treatment. The technology combines helium plasma and radiofrequency platform technology for skin tightening and has gained widespread acceptance among plastic surgeons and consumers globally.
According to an independent survey by Wakefield Research, 4 out of 5 board-certified or eligible cosmetic and plastic surgeons in the US consider Renuvion the #1 trusted body contouring technology. The NewBeauty Awards, a leading beauty industry program, selected winners after extensive testing and consultation with board-certified doctors and medical experts.
Renuvion, prodotto da Apyx Medical (NASDAQ: APYX), ha vinto il NewBeauty Award 2025 per il 'Miglior Rassodante Cutaneo Minimante Invasivo.' Questa tecnologia è il primo e unico dispositivo approvato dalla FDA per l'uso dopo la liposuzione nei trattamenti di rimodellamento del corpo.
Il riconoscimento arriva in un momento in cui le ricerche dei consumatori per 'pelle flaccida' sono aumentate del 168,7% nel 2024. L'efficacia di Renuvion è supportata da oltre 90 pubblicazioni cliniche basate su evidenze, offrendo risultati duraturi da un singolo trattamento. La tecnologia combina plasma di elio e tecnologia a radiofrequenza per il rassodamento della pelle ed ha guadagnato ampio consenso tra i chirurghi plastici e i consumatori a livello globale.
Secondo un'indagine indipendente condotta da Wakefield Research, 4 su 5 chirurghi plastici e cosmetici certificati o idonei negli Stati Uniti considerano Renuvion la tecnologia di rimodellamento del corpo più affidabile. I NewBeauty Awards, un programma di riferimento nel settore della bellezza, hanno selezionato i vincitori dopo ampi test e consultazioni con medici certificati e esperti del settore medico.
Renuvion, fabricado por Apyx Medical (NASDAQ: APYX), ha ganado el NewBeauty Award 2025 por 'Mejor Tensador de Piel Mínimamente Invasivo.' La tecnología es el primer y único dispositivo aprobado por la FDA para su uso después de la liposucción en tratamientos de contorno corporal.
Este reconocimiento llega en un momento en que las búsquedas de los consumidores sobre 'piel flácida' aumentaron un 168.7% en 2024. La efectividad de Renuvion está respaldada por más de 90 publicaciones clínicas basadas en evidencia, ofreciendo resultados duraderos con un solo tratamiento. La tecnología combina plasma de helio y tecnología de radiofrecuencia para el tensado de la piel y ha ganado amplia aceptación entre cirujanos plásticos y consumidores a nivel mundial.
Según una encuesta independiente realizada por Wakefield Research, 4 de cada 5 cirujanos plásticos y cosméticos certificados o elegibles en EE.UU. consideran a Renuvion la tecnología de contorno corporal más confiable. Los NewBeauty Awards, un programa líder en la industria de la belleza, seleccionaron a los ganadores después de pruebas exhaustivas y consultas con médicos certificados y expertos médicos.
Renuvion은 Apyx Medical (NASDAQ: APYX)에서 제조하였으며, '2025년 최소 침습 피부 탄력 개선기'로 NewBeauty Award를 수상했습니다. 이 기술은 체형 교정 치료에서 지방 흡입 후 사용을 위해 FDA 승인을 받은 최초이자 유일한 장치입니다.
이 인정은 2024년에 '처진 피부'에 대한 소비자 검색이 168.7% 증가한 가운데 이루어졌습니다. Renuvion의 효과는 90개 이상의 근거 기반 임상 출판물로 뒷받침되며, 단일 치료로 지속적인 결과를 제공합니다. 이 기술은 헬륨 플라즈마와 라디오 주파수 플랫폼 기술을 결합하여 피부를 탄력 있게 하며, 전 세계적으로 성형외과 의사와 소비자들 사이에서 널리 받아들여지고 있습니다.
Wakefield Research의 독립 조사에 따르면, 미국의 인증된 성형외과 의사 및 미용 의사 중 4명 중 5명이 Renuvion을 가장 신뢰받는 체형 교정 기술로 간주하고 있습니다. NewBeauty Awards는 광범위한 테스트와 인증된 의사 및 의료 전문가와의 상담 후 수상자를 선정했습니다.
Renuvion, fabriqué par Apyx Medical (NASDAQ: APYX), a remporté le NewBeauty Award 2025 pour le 'Meilleur Raffermissant Cutané Minimement Invasif.' Cette technologie est le premier et unique dispositif approuvé par la FDA pour une utilisation après une liposuccion dans les traitements de remodelage corporel.
Cette reconnaissance intervient alors que les recherches des consommateurs pour 'peau flasque' ont augmenté de 168,7 % en 2024. L'efficacité de Renuvion est soutenue par plus de 90 publications cliniques basées sur des preuves, offrant des résultats durables à partir d'un seul traitement. La technologie combine le plasma d'hélium et la technologie de radiofréquence pour le raffermissement de la peau et a gagné une large acceptation parmi les chirurgiens plastiques et les consommateurs à l'échelle mondiale.
Selon une enquête indépendante menée par Wakefield Research, 4 chirurgiens plastiques et esthétiques certifiés ou éligibles sur 5 aux États-Unis considèrent Renuvion comme la technologie de remodelage corporel la plus fiable. Les NewBeauty Awards, un programme de premier plan dans l'industrie de la beauté, ont sélectionné les lauréats après des tests approfondis et des consultations avec des médecins certifiés et des experts médicaux.
Renuvion, hergestellt von Apyx Medical (NASDAQ: APYX), hat den NewBeauty Award 2025 für 'Bestes minimal-invasives Hautstraffungsgerät' gewonnen. Die Technologie ist das erste und einzige von der FDA zugelassene Gerät, das nach einer Fettabsaugung in Körperformungsbehandlungen verwendet werden kann.
Diese Anerkennung erfolgt zu einem Zeitpunkt, an dem die Verbraucherrecherchen nach 'hängender Haut' im Jahr 2024 um 168,7 % gestiegen sind. Die Wirksamkeit von Renuvion wird durch über 90 evidenzbasierte klinische Publikationen gestützt, die langanhaltende Ergebnisse aus einer einzigen Behandlung liefern. Die Technologie kombiniert Heliumplasma und Radiofrequenz-Plattformtechnologie zur Hautstraffung und hat weltweit breite Akzeptanz bei plastischen Chirurgen und Verbrauchern gefunden.
Laut einer unabhängigen Umfrage von Wakefield Research betrachten 4 von 5 zertifizierten oder berechtigten kosmetischen und plastischen Chirurgen in den USA Renuvion als die vertrauenswürdigste Technologie zur Körperformung. Die NewBeauty Awards, ein führendes Programm in der Schönheitsindustrie, wählten die Gewinner nach umfangreichen Tests und Konsultationen mit zertifizierten Ärzten und medizinischen Experten aus.
- None.
- None.
Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin
Renuvion is the only device FDA-cleared for use after liposuction and is raising the bar for what consumers should expect from body contouring treatments. With more than 90 evidence-based clinical publications and long-lasting durable results from just one treatment, Renuvion has garnered a global fan base of consumers and plastic surgeons alike. This recognition comes at a pivotal time as consumers increasingly focus on the issue of loose and lax skin. According to Spate research, searches for "sagging skin" have surged by
"We are proud to have Renuvion's game-changing technology receive this accolade by a trusted authority in the aesthetic space," said Charlie Goodwin, President, and CEO of Apyx Medical. "Thousands of plastic surgeons rely on Renuvion, the #1 body contouring technology trusted by doctors3, to provide an effective solution to the challenges of loose skin."
NewBeauty editors tested thousands of products leading up to the 15th annual Awards Issue with the goal of selecting the most innovative beauty products, treatments, and trends. NewBeauty editors also collaborate with board-certified doctors and medical experts to determine the most effective, results-driven in-office treatments and post-procedure essentials.
To learn more about how Renuvion can address skin concerns, and find a provider near you, visit www.Renuvion.com.
1. Renuvion is intended for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue. Renuvion is intended for the coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
2. https://www.personalcareinsights.com/news/spate-search-data-suggests-innovative-opportunities-to-target-saggy-skin-and-nose-bumps.html
3. In an independent survey by Wakefield Research of 200 unaffiliated board certified or eligible cosmetic and plastic surgeons in the US where 4 out of 5 surgeons agree.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
Media Contact:
Kaplow Communications
Renuvion@kaplow.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/renuvion-wins-2025-newbeauty-award-for-best-minimally-invasive-skin-tightener-302409524.html
SOURCE Renuvion
FAQ
What makes Renuvion's 2025 NewBeauty Award significant for APYX investors?
How has the demand for Renuvion's skin tightening technology changed in 2024?
What clinical evidence supports Renuvion's effectiveness in 2025?
What percentage of US plastic surgeons trust Renuvion for body contouring in 2025?
What unique FDA clearance does Renuvion have for body contouring?
